CVS Health Corporation Company Profile (NYSE:CVS)

CVS Health Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVS."

CVS Health Corporation declared a quarterly dividend on Thursday, July 6th. Shareholders of record on Monday, July 24th will be paid a dividend of $0.50 per share on Thursday, August 3rd. This represents a $2.00 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Thursday, July 20th. View CVS Health Corporation's Dividend History.

CVS Health Corporation (NYSE:CVS) announced its earnings results on Tuesday, May, 2nd. The company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.07. The business had revenue of $44.51 billion for the quarter, compared to the consensus estimate of $44.20 billion. CVS Health Corporation had a net margin of 2.86% and a return on equity of 17.56%. The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.18 EPS. View CVS Health Corporation's Earnings History.

CVS Health Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, August, 8th 2017. View Earnings Estimates for CVS Health Corporation.

CVS Health Corporation updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $5.77-5.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.86. CVS Health Corporation also updated its Q2 guidance to $1.29-1.33 EPS.

19 analysts have issued 1-year price targets for CVS Health Corporation's shares. Their forecasts range from $77.00 to $120.00. On average, they expect CVS Health Corporation's stock price to reach $94.27 in the next year. View Analyst Ratings for CVS Health Corporation.

Here are some recent quotes from research analysts about CVS Health Corporation stock:

• 1. Guggenheim analysts commented, " Our recent meetings with CEO Larry Merlo, CFO Dave Denton, and VP-IR Nancy Christal further reinforced our confidence in 10% secular growth, which we believe the market is currently undervaluing, at a 13x P/E on somewhat depressed 2017E EPS. Bottom line, even in the face of secular gross margin erosion, in both segments, we believe the company should be able to grow EBIT by 5% on the back of a) natural growth in specialty Rx, b) increasingly rapid product innovation, c) a broadening set of productive relationships, and d) both COGS and SG&A reductions. In our view, this growth merits a valuation closer to a market multiple'we reiterate our Buy rating and $90 PT, implying 15% upside from current levels." (3/28/2017)
• 2. Evercore ISI analysts commented, "While the quarter proved generally uneventful and guidance was reiterated on the surface (albeit some moving parts below ' dollar profit targets were unchanged in our view ' much of the delta related to where 4Q came out vs mid-point and lower inflation outlook), investors have reacted negatively to the lack of clarity on several key issues with respect to business model risk that in our minds is unlikely to dissipate until later in the year. We think management did an admirable job on the DIR fee issue and a reasonable job on gross to net / rebates, but the reality is that policy noise is unlikely to dissipate and the outlook for 2018 won't start to gain clarity until the summer. We think once we get initial color on the PBM selling season, a better understanding of underlying pharmacy share shifts and profit headwinds and ultimately gain a better picture of 2018 the multiple may start to see some relief. Until then CVS shares remain inexpensive and highly leveraged to tax reform and it appears as if many years of execution are being overshadowed by a tough 18 month stretch. Given how far shares have fallen and in our view strong FCF yield support we retain our Buy rating but acknowledge the path to returns from here is likely most appropriate for those with a multi-year time horizon and a 'deep value' focus." (2/9/2017)
• 3. According to Zacks Investment Research, "CVS Health posted better-than-expected second-quarter with respected to adjusted EPS. However, revenues missed the Zacks Consensus Estimate. The company’s Pharmacy Services segment continues to benefit from growth in the Specialty Pharmacy business while the Retail Pharmacy segment is gaining from increased same-store sales. We take note of the recently completed Omnicare and Target Pharmacy buyouts which, according to CVS, are strategically perfect fits. CVS Health expects to benefit with multiple opportunities for driving enterprise value from Omnicare and Target in both the near and long term. CVS Health also expects to see market share gain in its specialty pharmacy suite of services with differentiated specialty offerings providing a high level of clinical support to patients. However, the competitive landscape remains tough. The tussle for market share gain in the PBM and retail space also warrants caution." (8/3/2016)

Some companies that are related to CVS Health Corporation include McDonald's Corporation (MCD), Inditex (IDEXY), The Priceline Group (PCLN), Walgreens Boots Alliance (WBA), Starbucks Corporation (SBUX), Costco Wholesale Corporation (COST), Lowe's Companies (LOW), JD.com (JD), Kering Unspon (PPRUY), TJX Companies, Inc. (The) (TJX), Hennes & Mauritz AB (HNNMY), Wal-Mart de Mexico SAB de CV (WMMVY), eBay (EBAY), Target Corporation (TGT), Ctrip.com International (CTRP), Yum! Brands (YUM), Expedia (EXPE) and Kroger Company (The) (KR).

CVS Health Corporation's management team includes the folowing people:

• David Wyatt Dorman, Independent Chairman of the Board
• Larry J. Merlo, President, Chief Executive Officer, Director
• David M. Denton, Chief Financial Officer, Executive Vice President
• Jonathan C. Roberts, Chief Operating Officer, Executive Vice President
• Lisa G. Bisaccia, Chief Human Resource Officer, Executive Vice President
• Stephen J. Gold, Executive Vice President, Chief Information Officer
• Thomas M. Moriarty, Executive Vice President, General Counsel, Chief Health Strategy Officer
• Troyen A. Brennan M.D., Executive Vice President, Chief Medical Officer
• Helena B. Foulkes, Executive Vice President, President of CVS - Pharmacy
• J. David Joyner, Executive Vice President

CVS Health Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.52%), APG Asset Management N.V. (0.38%), State Treasurer State of Michigan (0.20%), Swedbank (0.17%), Focused Investors LLC (0.17%) and US Bancorp DE (0.16%). Company insiders that own CVS Health Corporation stock include Andrew Sussman, David M Denton, Eva C Boratto, Helena Foulkes, Jonathan C Roberts, Larry J Merlo, Stephen J Gold and Troyen A Brennan. View Institutional Ownership Trends for CVS Health Corporation.

CVS Health Corporation's stock was sold by a variety of institutional investors in the last quarter, including Focused Investors LLC, Forsta AP Fonden, Swedbank, Rockefeller Financial Services Inc., First Quadrant L P CA, Hexavest Inc., DnB Asset Management AS and Armstrong Shaw Associates Inc. CT. Company insiders that have sold CVS Health Corporation stock in the last year include Andrew Sussman, David M Denton, Eva C Boratto, Helena Foulkes, Jonathan C Roberts and Troyen A Brennan. View Insider Buying and Selling for CVS Health Corporation.

CVS Health Corporation's stock was purchased by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., State Treasurer State of Michigan, Bank of Montreal Can, Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., Chevy Chase Trust Holdings Inc., Oregon Public Employees Retirement Fund and Horan Capital Management. View Insider Buying and Selling for CVS Health Corporation.

Shares of CVS Health Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CVS Health Corporation stock can currently be purchased for approximately $77.03.